Collaboration with patient caregiver, patient advocate, and physician to highlight the barriers, benefits, and solutions for shared decision-making (SDM) in prostate cancer

Yuan Wang^a, Pooja Merchant^a, Günther Carl^b, Jan Manarite^c, Martin Bögemann^d, and Yaswant Dayaram^a

^aBayer Healthcare LLC, Whippany, NJ, USA; ^bEuropa Uomo, Antwerp, Belgium; ^cCancer ABCs, Brooklyn, NY, USA; ^dDepartment of Urology, Münster University Medical Center, Münster, Germany

Introduction

What is shared decision-making?

Shared decision-making is a process involving collaboration and communication between patients/caregivers and clinicians, to reach a mutual decision about treatment/care¹

• There is now a range of prostate cancer treatment options available,

Best practice example partnership between patient authors and publications and patient engagement teams

Bayer publications and patient engagement teams partnered with individuals from the prostate cancer



Barriers to shared decision-making

What are the barriers to shared decision-making for the patient/ caregiver? • Feeling overwhelmed by the diagnosis^{5,6}



- each with potential side effects that can adversely affect patients' lives; therefore, there are many factors to consider when making a decision about treatments
- To optimize the prostate cancer care experience, patients and their caregivers should be actively involved in shared decision-making with clinicians about their treatment
- Patients should be empowered to participate in shared decision-making through the provision of the right tools and resources for making an informed decision

Objective

- We wanted to inform the development of best practice solutions to shared decision-making by collaborating with patient/caregiver and physician representatives to understand barriers and identify opportunities to optimize patient/caregiver-clinician interactions
- In this process, we also wanted to establish a close partnership with patient/caregiver/physician authors during the development of a patient-relevant publication

Benefits of shared decision-making

care community Bayer professionals facilitated an in-depth discussion that involved a prostate cancer patient advocate, a caregiver, and a urologist, promoting an open dialogue about the benefits, barriers, and solutions to shared decision-making from different perspectives • To inform the development of best practice solutions for shared decision-making, all authors agreed for their discussion to be supplemented by evidence-based information from a literature search and the Europa Uomo patient survey

Limited health literacy⁷

Lack of time to reflect on information provided⁸

• Lack of confidence in ability to make decision^{6,9}

• Lack of access to accurate, credible plain-language resources^{8,10,11}

Language differences¹²

What are barriers to shared decision-making for the clinician?

• Lack of confidence in patient's ability to make decision¹³

• Limited time to discuss treatment options with patients⁴

 Reimbursement pathways that disincentivize multidisciplinary care¹⁴

 Specialty-specific preferences for certain treatments, limiting treatment options discussed with patients^{4,13,15}

Best practice for shared decision-making

Patients/caregivers are concerned about patients' personal circumstances, needs, and goals²⁻⁴

> Treatment outcomes are optimized when patients/ caregivers and clinicians align on treatment goals³

> > Clinicians' decisions are

Database: PubMed (https://pubmed.ncbi. nlm.nih.gov/) Search terms: "shared decision making" AND "prostate cancer" Search date: November 17, 2022 Results retrieved: 473 articles (of which 171 were relevant to the objective)

EUROPA UOMO

The Voice of Men with Prostate Cancer in Europe

- Europa Uomo patient survey (https://www.europa-uomo.org/ who-we-are/quality-of-life-2/the-euproms-study/) A European advocacy group for patients with prostate cancer conducted a 20-minute online survey to understand patients' experiences and quality of life after prostate cancer treatment
- Survey used validated quality-of-life questionnaires
- Survey is ongoing with responses from 6,000 patients
- Data from the first round of surveys was used; completed in 2019 by 3,000 patients from 25 European countries

Benefits • **Barriers** • **Solutions**

Discussion

Publication professionals can increase the relevance and extend the reach of publications to broader audiences by involving patient, caregiver, and patient advocate authors, ensuring that their voices are represented within publications

Through our partnership with patient caregiver/patient advocate/clinician authors, we highlight the benefits, barriers, and solutions for shared decision-making and show that successful shared decisionmaking relies on the collaboration of:

Optimized shared decision-making can be achieved through patient/ caregiver and clinician engagement





- Multidisciplinary care teams
- Patients/caregivers
- Family and support networks

Publication professionals can also play a part in the shared decision-making process by supporting the development of plain language summaries and patient-friendly publications to enhance patient knowledge while demonstrating transparency and equity in publication best practices

References

- 1. Steffensen KD, et al. Lessons in integrating shared decision-making into cancer care. J Oncol Pract 2018;14:229–235.
- 2. Scherr KA, et al. Physician recommendations trump patient preferences in prostate cancer treatment decisions. *Med Decis Making* 2017;37:56–69.
- 3. Eliasson L, et al. Patients' preferences for the treatment of metastatic castrate-resistant prostate cancer: A discrete choice experiment. Clin Ther 2017;39:723-737.
- 4. Ankolekar A, et al. Development and validation of a patient decision aid for prostate cancer therapy: From paternalistic towards participative shared decision making. BMC Med Inform Decis Mak 2019;19:130.
- 5. Dekker J, et al. Management of distress in patients with cancer are we doing the right thing? Ann Behav Med 2020;54:978–984.
- 6. Løwe MM, et al. The balance of patient involvement: Patients' and health professionals' perspectives on decision-making in the treatment of advanced prostate cancer. Qual Health Res 2021;31:29-40.
- 7. Nguyen DD, et al. Impact of health literacy on shared decision making for prostate-specific antigen screening in the United States. *Cancer* 2021;127:249–256.
- 8. Netsey-Afedo MML, et al. No time for reflection: Patient experiences with treatment-related decision-making in advanced prostate cancer. Scand J Caring Sci 2020;34:880-888.
- 9. Schumacher FA, et al. Treatment decision-making in metastatic prostate cancer: Perceptions of locus of control among patient, caregiver, and physician triads. Patient Prefer Adherence 2022;16:235–244.
- 10. Loeb S, et al. Dissemination of misinformative and biased information about prostate cancer on YouTube. Eur Urol 2019;75:564–567.
- 11. Daskivich TJ, et al. Variation in communication of competing risks of mortality in prostate cancer treatment consultations. J Urol 2022;208:301–308. 12. Michel J, et al. Improving shared decision making in Latino men with prostate cancer: A thematic analysis. MDM Policy Pract 2021;6:23814683211014180.
- 13. Holmes A, et al. A systematic scoping review of multidisciplinary cancer team and decision-making in the management of men with advanced prostate cancer.
- World J Urol 2021;39:297–306.
- 14. Wilkes M, et al. Discussing uncertainty and risk in primary care: Recommendations of a multi-disciplinary panel regarding communication around prostate cancer screening. J Gen Intern Med 2013;28:1410–1419.
- 15. Paudel R, et al. Implementation of prostate cancer treatment decision aid in Michigan: A qualitative study. Implement Sci Commun 2021;2:27.
- 16. Deschamps A, O'Sullivan J. A patient-centred approach to managing prostate cancer. Available at https://c.peervoice.com/programs/340205253/downloads/ PV_transcript_XUV_EN.pdf (accessed February 20, 2023).
- 17. Herlemann A, et al. Health care delivery for metastatic hormone-sensitive prostate cancer across the globe. *Eur Urol Focus* 2019;5:155–158.
- 18. Europa Uomo available at https://www.europa-uomo.org/who-we-are/quality-of-life-2/the-euproms-study/ (accessed February 20, 2023).
- 19. Jones M, Pietilä A. Expertise, advocacy and activism: A qualitative study on the activities of prostate cancer peer support workers. *Health* 2020;24:21–37.
- 20. King K, et al. The role of plain-language summaries in communicating clinical trial data. Available at https://medicalaffairs.org/plain-language-summaries-clinicaltrial/ (accessed February 20, 2023) with Medical Affairs Professional Society.
- 21. Fagerlin A, et al. Head to head randomized trial of two decision aids for prostate cancer. BMC Med Inform Decis Mak 2021;21:154.
- 22. Baptista S, et al. Comparison of explicit values clarification method (VCM), implicit VCM and no VCM decision aids for men considering prostate cancer screening: Protocol of a randomized trial. BMC Med Inform Decis Mak 2020;20:78.
- 23. Allen JD, et al. Preparing African American men to make informed prostate cancer screening decisions: Development and pilot testing of an interactive online decision aid. JMIR Mhealth Uhealth 2020;8:e15502.
- 24. Bagshaw HP, et al. A personalized decision aid for prostate cancer shared decision making. BMC Med Inform Decis Mak 2021;21:374.

Acknowledgments

Medical writing support was provided by Clare Bellward and Sara Black, ISMPP CMPPTM, of OPEN Health Communications (London, UK), with financial support from Bayer HealthCare Pharmaceuticals (Whippany, NJ, USA).

Disclosures

Yuan Wang: Employment: Bayer; Pooja Merchant: Employment; Bayer; Carl Günther: nothing to disclose; Jan Manarite; nothing to disclose; Martin Bögemann; Employment: Janssen; Honorarium: Janssen-Cilag, Astellas Pharma, Bayer/Vital, Sanofi/Aventis, MSD, Bristol Myers Squibb, Pfizer, Novartis, Ipsen, EUSA Pharma, Merck, Eisai, Amgen, AstraZeneca, Roche, Advanced Accelerator Applications; Consulting or Advisory Role: Bayer, Janssen-Cilag, Astellas Pharma, AstraZeneca, MSD, Bristol Myers Squibb, IPSEN, Roche, Novartis, Merck, Sanofi, Eisai; Research Funding: Janssen-Cilag, IPSEN; Travel, Accommodations, Expenses: Janssen-Cilag, Bayer, Amgen, BMS GmbH & Co KG; Yaswant Dayaram: Employment: Bayer.

Presented at ISMPP: International Society for Medical Publication Professionals 19th annual meeting, Washington, DC, USA, April 24–26, 2023. Corresponding author contact: yuan.wang2@bayer.com



